...Rahul Deb; Natthawadee Laokulrath; Leena Chagla; Puay Hoon Tan Background: Breast pathology reporting, especially for breast cancer, has evolved through the years, from terse succinct diagnostic conclusions with scant histological details to the current comprehensive reporting guidelines issued...

... of synchronous carcinoma in the ipsilateral or contralateral breast were excluded. Ninety-eight cases of in situ or invasive carcinoma within a PT were identified. Across the grades of PTs, there was a similar proportion of invasive carcinomas compared to in situ lesions. Malignant PT correlates with a higher...

...Raza S. Hoda; Edi Brogi; Hannah Y. Wen Immunohistochemistry techniques have been incorporated into surgical pathology for nearly a half-century and have since become intimately intertwined with its practice. In the realm of breast pathology, immunohistochemistry serves several purposes, including...

...Helen Bartlett; Maiar Elghobashy; Nayneeta Deshmukh; Rashmi Rao; Abeer M. Shaaban Introduction: Non-epithelial primary mammary osteosarcomas are extremely rare. The differentials include metaplastic carcinoma and malignant phyllodes tumour. This is the first published case of primary breast...

... renal dialysis. Case: This is a 57-year-old female who presented to breast clinic with unilateral severe pain and lumpiness of her breast. On mammography, calcifications were identified which were associated with focal lesions on ultrasound. An image-guided core biopsy showed numerous foci...

...Michael S. Toss; Kim Billingham; Isioma U. Egbuniwe; Filipa Moreno; Areeg Abass; Emad A. Rakha Background: Papillary tumours of the breast are diagnostically challenging lesions and represent a wide spectrum of diseases from papilloma to invasive papillary carcinoma. A rare subtype of breast...

... immunohistochemical staining for the 7 CAF-related proteins. We classified DCIS into luminal type, human epidermal growth factor receptor-2 (HER-2) type, and triple negative breast cancer (TNBC) according to the immunohistochemical results for estrogen receptor, progesterone receptor, and HER-2. We also classified...

...Nzechukwu Zimudo Ikeri; Olubanji Ajibola Oguntunde; Uche Igbokwe; Fatimah Biade Abdulkareem; Adekunbiola Aina Banjo Objective: There are significant epidemiological and biological differences between breast cancer in blacks and whites which have wide-reaching implications for the institution...

...Laura Herrero; Dolores Naranjo-Hans; Manel Solé; Gorane Santamaría; Xavier Bargalló; Martín Velasco; Pedro Luis Fernández Background: Amyloidosis involving the breast is a rare finding and it may present as a solitary mass called 'amyloid tumor'. According to the largest case series, the amyloid...

...Bence Kővári; A. Marcell Szász; Janina Kulka; Zlatko Marušić; Bozena Šarčević; László Tiszlavicz; Gábor Cserni Objective: The identification of myoepithelial cells (MEC) is a valuable clue in the differential diagnosis of breast lesions. A series of breast lesions with occasional absence...

...Ji-Ye Kim; Woo Hee Jung; Ja Seung Koo Objective: The purpose of the current study is to understand the clinicopathological implications of redox proteins in association with androgen receptor (AR) and HER-2 status in estrogen receptor (ER)-negative breast cancers through evaluation...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. TNBC serves as a breast cancer subtype with negative expression of ER, PR and HER-2 in approximately 20% of all breast cancers [ 5 ]. TNBC also represents a heterogeneous...

...Dokyung Kim; Woo-Hee Jung; Ja Seung Koo Objective: The purpose of this study was to investigate the expression of MUC1, MUC2, MUC5AC and MUC5B in breast mucinous lesions. Methods: Immunohistochemical staining of MUC1, MUC2, MUC5AC, MUC5B and synaptophysin was performed in 78 cases of mucinous...

... and/or overexpression of c-erbB-2 in breast adenocarcinomas occurs frequently and its occurrence implies a more advanced malignancy. This functional tumor marker is readily identified by appropriate DNA and antibody probes. The large external domain of the c-erbB-2 gene product is a promising target...

...Jolanta Rzymowska Seventy patients with breast cancer at various clinical stages and 15 patients with fibroadenoma were investigated. After chemotherapy, a significant increase in total triglycerides in malignant breast cancer patients before and after menopause has been observed. The increase...